Has Mary Klix, MD received payments from drug or device companies?

Yes. Drug and device makers reported $12,630 in general payments to Mary Klix, MD across 465 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mary Klix, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mary Klix, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mary Klix, MD

Hematology & Oncology · Anchorage, AKNPI 1669447595

Payments from drug & device makers

$12,630in general payments, 2019–2025

Across 465 payments — averaging $27.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$1K
Rigel Pharmaceuticals, Inc.$1K
E.r. Squibb & Sons, L.L.C.$651
Pfizer$635
Bristol Myers Squibb$593
Astellas Pharma US Inc$547
plus $7K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	51	$1,327
Rigel Pharmaceuticals, Inc.	7	$1,173
E.r. Squibb & Sons, L.L.C.	25	$651
Pfizer	28	$635
Bristol Myers Squibb	23	$593
Astellas Pharma US Inc	15	$547
Incyte Corporation	12	$541
Novartis	26	$519
Johnson & Johnson(2 entities)	27	$502
Pharmacyclics LLC, An Abbvie Company	14	$413
Amgen	14	$406
Seagen Inc.	17	$395
Genentech USA, Inc.	16	$338
AbbVie	9	$314
GSK	12	$249
Merck	8	$228
Boehringer Ingelheim	8	$194
Daiichi Sankyo Inc.	9	$193
Bayer	9	$186
Taiho Oncology, Inc.	6	$161
Sobi, Inc	3	$150
Adaptive Biotechnologies Corporation	3	$142
Ipsen Biopharmaceuticals, Inc	2	$132
Geron Corporation	1	$125
Regeneron Healthcare Solutions, Inc.	4	$122
Eisai Inc.	5	$114
Coherus Oncology, Inc.	5	$112
Clovis Oncology, Inc.	6	$99
Intuitive Surgical	3	$96
EMD Serono, Inc.	5	$89
Tersera Therapeutics LLC	3	$88
Lilly USA, LLC	5	$87
Acrotech Biopharma Inc.	4	$78
Foundation Medicine, Inc.	3	$72
AVEO Pharmaceuticals, Inc.	4	$70
Chiesi USA, Inc.	3	$70
ASD Specialty Healthcare, LLC	2	$69
Gilead(2 entities)	3	$68
Deciphera Pharmaceuticals Inc.	3	$65
Stemline Therapeutics Inc.	3	$64
Agios Pharmaceuticals, Inc.	3	$64
Jazz Pharmaceuticals Inc.	3	$56
Exelixis Inc.	3	$54
Epizyme, Inc.	3	$53
Sanofi	3	$51
Genmab U.S., Inc.	2	$50
Aurobindo Pharma USA, Inc.	3	$50
Springworks Therapeutics, Inc.	2	$47
Blueprint Medicines Corporation	2	$44
Heron Therapeutics, Inc.	2	$40
Puma Biotechnology, Inc.	2	$39
Array Biopharma Inc	2	$38
Myovant Sciences Inc.	2	$36
Dova Pharmaceuticals	2	$36
Celltrion USA Inc.	2	$34
Takeda Pharmaceuticals U.S.A., Inc.	1	$29
Immunocore Limited	1	$28
Pharmacosmos Therapeutics Inc.	1	$26
Pharmaessentia USA Corporation	1	$25
Karyopharm Therapeutics Inc.	1	$25

How this compares

Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$588,031

Medicare patients

332

Services billed

22,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Anchorage

Steven LiuAnchorage$6.9M
Theodore KimAnchorage$1.4M
Max RabinowitzAnchorage$14K
Mary StewartAnchorage$9K
Kendal WebbAnchorage$8K
Natalie WallaceAnchorage$8K
Shannon SmileyAnchorage$6K
Charles BuessAnchorage$5K
Anusiyanthan MariampillaiAnchorage$4K
Ellen ChirichellaAnchorage$2K

See the full list for Alaska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →